Valneva: new positive data in CHIKV

(CercleFinance.com) - Valneva announces further positive results in adolescents from the pivotal Phase 3 study of its single-dose chikungunya virus vaccine (CHIKV), from the most recent analysis assessing safety and immunogenicity at six months.


The results at day 180 confirmed the initial positive data previously announced, and should enable Valneva to submit an application to extend the use of the Ixchiq vaccine in adolescents aged 13 to 17.

These results should also enable the vaccine to be licensed in Brazil, which would then constitute the first marketing authorization for use in an endemic population, Valneva adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.